(NASDAQ: TVTX) Travere Therapeutics's forecast annual revenue growth rate of 34.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.62%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.19%.
Travere Therapeutics's revenue in 2026 is $435,827,000.On average, 16 Wall Street analysts forecast TVTX's revenue for 2026 to be $63,142,410,610, with the lowest TVTX revenue forecast at $50,856,070,667, and the highest TVTX revenue forecast at $75,419,803,321. On average, 13 Wall Street analysts forecast TVTX's revenue for 2027 to be $79,936,366,388, with the lowest TVTX revenue forecast at $59,071,419,732, and the highest TVTX revenue forecast at $107,098,375,419.
In 2028, TVTX is forecast to generate $94,840,666,620 in revenue, with the lowest revenue forecast at $74,135,875,429 and the highest revenue forecast at $131,792,737,671.